AL FEBRE: Open Payments
NPI 1275834418 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$863 in 36 payments from 12 companies in 2025. Trend: 2023 $914 · 2024 $630 · 2025 $863
Food & beverage: $863
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 3 | $177 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $156 |
| Gilead Sciences, Inc. | 1 | $114 |
| Madrigal Pharmaceuticals | 4 | $101 |
| Ipsen Biopharmaceuticals, Inc | 4 | $93 |
| ABBVIE INC. | 4 | $67 |
| Celltrion USA Inc. | 3 | $54 |
| Ardelyx, Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
Products named: TREMFYA, Livdelzi, REZDIFFRA, TRULANCE, IQIRVO, SKYRIZI, RELISTOR, VEGZELMA.
Industry payments across FL — which companies pay providers there.
